Literature DB >> 2284289

Chemotherapy for endocrine resistant cancer of the prostate.

M A Eisenberger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2284289

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN： 0361-7742


× No keyword cloud information.
  3 in total

1.  LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.

Authors:  Weiping Leng; Qingzuo Liu; Shidong Zhang; Dekang Sun; Yongshun Guo
Journal:  Cancer Biol Ther       Date:  2020-11-03       Impact factor: 4.742

2.  Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.

Authors:  D Samid; S Shack; C E Myers
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

3.  Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide.

Authors:  Keiichiro Uemura; Kiyoaki Nishihara; Tokumasa Hayashi; Katsuro Tomiyasu; Kei Matsuoka
Journal:  J Infect Chemother       Date:  2011-12-28       Impact factor: 2.211
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.